Safety and efficacy of regional citrate anticoagulation in continuous blood purification treatment of patients with multiple organ dysfunction syndrome

B Tuerdi, L Zuo, H Sun, K Wang, Z Wang, G Li, B Tuerdi, L Zuo, H Sun, K Wang, Z Wang, G Li

Abstract

The aim of this study was to discuss the safety and efficacy of regional citrate anticoagulation (RCA) on continuous blood purification (CBP) during the treatment of multiple organ dysfunction syndrome (MODS). Thirty-five patients with MODS were divided into two groups: the local citrate anticoagulation (RCA) group, and the heparin-free blood purification (hfBP) group. The MODS severity was assessed according to Marshall's MODS score criteria. Blood coagulation indicators, blood pressure, filter lifespan, filter replacement frequency, anticoagulation indicators, and main metabolic and electrolyte indicators were analyzed and compared between RCA and hfBP groups. RCA resulted in lower blood pressure than hfBP. The filter efficacy in RCA treatment was longer than in the hfBP group. The blood clearance of creatine, blood urea nitrogen and uric acid was better in the RCA group. RCA also led to higher pH than hfBP. Neither treatment resulted in severe bleeding events. In addition, MODS score was positively correlated with prothrombin time and activated partial thromboplastin time but negatively correlated with platelet concentration. RCA is a safer and more effective method in CBP treatment; however, it could also lead to low blood pressure and blood alkalosis.

References

    1. Walsh CR. Multiple organ dysfunction syndrome after multiple trauma. Orthop Nurs. 2005;24:324–333. quiz 334–335.
    1. Schmidt H, Lotze U, Ghanem A, Anker SD, Said SM, Braun-Dullaeus R, et al. Relation of impaired interorgan communication and parasympathetic activity in chronic heart failure and multiple-organ dysfunction syndrome. J Crit Care. 2014;29:367–373. doi: 10.1016/j.jcrc.2013.12.015.
    1. Kochanek KD, Murphy SL, Anderson RN, Scott C. Deaths: final data for 2002. Natl Vital Stat Rep. 2004;53:1–115.
    1. Kung HC, Hoyert DL, Xu J, Murphy SL. Deaths: final data for 2005. Natl Vital Stat Rep. 2008;56:1–120.
    1. Rico MP, Fernandez Sarmiento J, Rojas Velasquez AM, Gonzalez Chaparro LS, Gastelbondo Amaya R, Mulett Hoyos H, et al. Regional citrate anticoagulation for continuous renal replacement therapy in children. Pediatr Nephrol. 2017;32:719. doi: 10.1007/s00467-016-3568-1.
    1. Kielstein JT, Kretschmer U, Ernst T, Hafer C, Bahr MJ, Haller H, et al. Efficacy and cardiovascular tolerability of extended dialysis in critically ill patients: a randomized controlled study. Am J Kidney Dis. 2004;43:342–349. doi: 10.1053/j.ajkd.2003.10.021.
    1. Kumar VA, Craig M, Depner TA, Yeun JY. Extended daily dialysis: A new approach to renal replacement for acute renal failure in the intensive care unit. Am J Kidney Dis. 2000;36:294–300. doi: 10.1053/ajkd.2000.8973.
    1. Baglin T. Disseminated intravascular coagulation: diagnosis and treatment. BMJ. 1996;312:683–687. doi: 10.1136/bmj.312.7032.683.
    1. Berbece AN, Richardson RM. Sustained low-efficiency dialysis in the ICU: cost, anticoagulation, and solute removal. Kidney Int. 2006;70:963–968. doi: 10.1038/sj.ki.5001700.
    1. Pannu N, Gibney RN. Renal replacement therapy in the intensive care unit. Ther Clin Risk Manag. 2005;1:141–150. doi: 10.2147/tcrm.1.2.141.62908.
    1. Tan HK, Yang WS, Chow P, Lui HF, Choong HL, Wong KS. Anticoagulation minimization is safe and effective in albumin liver dialysis using the molecular adsorbent recirculating system. Artif Organs. 2007;31:193–199. doi: 10.1111/j.1525-1594.2007.00364.x.
    1. Faybik P, Bacher A, Kozek-Langenecker SA, Steltzer H, Krenn CG, Unger S, et al. Molecular adsorbent recirculating system and hemostasis in patients at high risk of bleeding: an observational study. Crit Care. 2006;10:R24. doi: 10.1186/cc3985.
    1. Abdul Cader R, Abdul Gafor H, Mohd R, Yen Kong W, Arshad N, Kong N. Coupled Plasma Filtration and Adsorption (CPFA): A Single Center Experience. Nephrourol Mon. 2013;5:891–896. doi: 10.5812/numonthly.11904.
    1. Gasparovic V, Filipovic-Grcic I, Merkler M, Pisl Z. Continuous renal replacement therapy (CRRT) or intermittent hemodialysis (IHD) - what is the procedure of choice in critically ill patients? Ren Fail. 2003;25:855–862. doi: 10.1081/JDI-120024300.
    1. Xing R, Jin Y, Sun L, Yang L, Li C, Li Z, et al. Interleukin-21 induces migration and invasion of fibroblast-like synoviocytes from patients with rheumatoid arthritis. Clin Exp Immunol. 2016;184:147–158. doi: 10.1111/cei.12751.
    1. Vargas Hein O, Kox WJ, Spies C. Anticoagulation in continuous renal replacement therapy. Contrib Nephrol. 2004;144:308–316. doi: 10.1159/000078898.
    1. Oudemans-van Straaten HM. Citrate anticoagulation for continuous renal replacement therapy in the critically ill. Blood Purif. 2010;29:191–196. doi: 10.1159/000245646.
    1. Morabito S, Pistolesi V, Tritapepe L, Zeppilli L, Polistena F, Strampelli E, et al. Regional citrate anticoagulation in cardiac surgery patients at high risk of bleeding: a continuous veno-venous hemofiltration protocol with a low concentration citrate solution. Crit Care. 2012;16:R111. doi: 10.1186/cc11403.
    1. Palsson R, Niles JL. Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kidney Int. 1999;55:1991–1997. doi: 10.1046/j.1523-1755.1999.00444.x.
    1. Schmitz M, Taskaya G, Plum J, Hennersdorf M, Sucker C, Grabensee B, et al. Continuous venovenous haemofiltration using a citrate buffered substitution fluid. Anaesth Intensive Care. 2007;35:529–535.
    1. Onishi S, Yoshino S. Cathartic-induced fatal hypermagnesemia in the elderly. Intern Med. 2006;45:207–210. doi: 10.2169/internalmedicine.45.1482.
    1. Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med. 2004;30:260–265. doi: 10.1007/s00134-003-2047-x.
    1. Amanzadeh J, Reilly RF., Jr Anticoagulation and continuous renal replacement therapy. Semin Dial. 2006;19:311–316. doi: 10.1111/j.1525-139X.2006.00178.x.
    1. Kramer L, Bauer E, Joukhadar C, Strobl W, Gendo A, Madl C, et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med. 2003;31:2450–2455. doi: 10.1097/01.CCM.0000084871.76568.E6.
    1. Hetzel GR, Schmitz M, Wissing H, Ries W, Schott G, Heering PJ. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrol Dial Transplant. 2011;26 doi: 10.1093/ndt/gfq575.
    1. Tolwani AJ, Prendergast MB, Speer RR, Stofan BS, Wille KM. A practical citrate anticoagulation continuous venovenous hemodiafiltration protocol for metabolic control and high solute clearance. Clin J Am Soc Nephrol. 2006;1:79–87. doi: 10.2215/CJN.00040505.
    1. Zaloga GP. Hypocalcemia in critically ill patients. Crit Care Med. 1992;20:251–262. doi: 10.1097/00003246-199202000-00014.
    1. Saner FH, Treckmann JW, Geis A, Losch C, Witzke O, Canbay A, et al. Efficacy and safety of regional citrate anticoagulation in liver transplant patients requiring post-operative renal replacement therapy. Nephrol Dial Transplant. 2012;27:1651–1657. doi: 10.1093/ndt/gfr510.
    1. Stucker F, Ponte B, Tataw J, Martin PY, Wozniak H, Pugin J, et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Crit Care. 2015;19:91. doi: 10.1186/s13054-015-0822-z.
    1. Slowinski T, Morgera S, Joannidis M, Henneberg T, Stocker R, Helset E, et al. Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study. Crit Care. 2015;19:349. doi: 10.1186/s13054-015-1066-7.
    1. Kawarazaki H, Uchino S. Validity of low-efficacy continuous renal replacement therapy in critically ill patients. Anaesthesiol Intensive Ther. 2016;48:191–196. doi: 10.5603/AIT.a2016.0029.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe